Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%
Ph early_phase_1
2
50%
Ph phase_4
1
25%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

terminated125%
recruiting125%
unknown125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingearly_phase_1

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

NCT04469842
completedphase_3

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
terminatedearly_phase_1

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

NCT03380936
unknownphase_4

Veloxis de Novo Kidney Transplant ECSWD

NCT03828682

Clinical Trials (4)

Showing 4 of 4 trials
NCT04469842Early Phase 1

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Recruiting
NCT03289650Phase 3

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

Completed
NCT03380936Early Phase 1

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Terminated
NCT03828682Phase 4

Veloxis de Novo Kidney Transplant ECSWD

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4